Research programme: autoimmune disorder therapeutics - Advesya
Latest Information Update: 23 Jan 2025
Price :
$50 *
At a glance
- Originator Advesya
- Class
- Mechanism of Action Interleukin-1 receptor accessory protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders
Most Recent Events
- 27 Dec 2024 Early research in Autoimmune disorders in France (unspecified route) prior to December 2024 (Advesya pipeline, December 2024)